|
|
News Breaks | | | | February 25, 2013 | | 09:18 EDT |  | AFFY | Affymax plunges after negative Omontys reactions, levels to watch
Shares are at a dramatic new low following a recall of Omontys due to serious hypersensitivity reactions. Several firms have cut targets to as low $4 per share, with expectations the stock could approach the cash level of the stock at the $2 area, which is what we are seeing this morning. Piper Jaffray, RW Baird, Stifel Nicolaus, and JMP Securities have all downgraded the stock. At the current price of $2.53, there isn't established resistance until $3.93, the prior life low for the stock. There is also no established support other than the $2 cash level mentioned by Piper Jaffray as a possible magnet for share price. | |
|
News For AFFY From The Last 14 Days Check below for free stories on AFFY the last two weeks. |
|
|
| May 14, 2013 | | 18:15 EDT |  | AFFY | Affymax CEO to step down
 Subscribe for More Information | | | 07:18 EDT |  | AFFY | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. | |
|
|
|
|
|
|
